AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34758252 — intervention group
Group type: COMPARATOR
Intervention: Ramipril
Number of subjects: 5661
Study 33057643 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Standardized Patients (VSP) training
Number of subjects: 120
Study 33057643 — intervention group
Group type: COMPARATOR
Intervention: Academic study (Control)
Number of subjects: 120
Study 35065334 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute stress condition
Number of subjects: 80
Study 35065334 — intervention group
Group type: COMPARATOR
Intervention: No-stress control condition
Number of subjects: 80
Study 32746941 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Number of subjects: 358
Study 32746941 — intervention group
Group type: COMPARATOR
Intervention: SSRIs (considered as a single group)
Number of subjects: 358
Study 32259228 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin plus Olaratumab (75 mg/m2 + 20 mg/kg in cycle 1 and 15 mg/kg in subsequent cycles)
Number of subjects: 509
Study 32259228 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin plus Placebo (75 mg/m2 + placebo)
Number of subjects: 509
Study 32259228 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin plus Olaratumab
Number of subjects: 509
Study 32259228 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin plus Placebo
Number of subjects: 509
Study 35688272 — intervention group
Group type: EXPERIMENTAL
Intervention: Particulate bone graft filling material (75% autogenous bone chips and 25% deproteinized bovine bone mineral)
Number of subjects: 22
Study 35688272 — intervention group
Group type: COMPARATOR
Intervention: Unfilled gap (spontaneous bone healing)
Number of subjects: 22
Study 34480008 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (SB; 0.3 g/kg body mass) with high-intensity (HI) warm-up
Number of subjects: 12
Study 34480008 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (SB; 0.3 g/kg body mass) with low-intensity (LI) warm-up
Number of subjects: 12
Study 34480008 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA; maltodextrin) with high-intensity (HI) warm-up
Number of subjects: 12
Study 34480008 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA; maltodextrin) with low-intensity (LI) warm-up
Number of subjects: 12
Study 36148560 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded sample size re-estimation (BSSR) method
Number of subjects: 0
Study 36148560 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical treatment to reduce exacerbation rate
Number of subjects: 0
Study 32144167 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart bolus calculator informed by real-time insulin sensitivity estimates
Number of subjects: 15
Study 32144167 — intervention group
Group type: COMPARATOR
Intervention: Standard bolus calculator
Number of subjects: 15
Study 35098608 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-induced myofascial release protocol using a foam roller
Number of subjects: 25
Study 32029010 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-delivered telephone interpersonal psychotherapy (IPT)
Number of subjects: 241
Study 32029010 — intervention group
Group type: COMPARATOR
Intervention: Standard locally available care
Number of subjects: 241
Study 35918696 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound (TUS)
Number of subjects: 38
Study 35918696 — intervention group
Group type: COMPARATOR
Intervention: Injection of local anesthetic (IA)
Number of subjects: 38
Study 33675600 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental VOR adaptation exercises
Number of subjects: 24
Study 33675600 — intervention group
Group type: COMPARATOR
Intervention: x1 gaze-stabilizing exercises (control)
Number of subjects: 24
Study 33084524 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Restriction (SR)
Number of subjects: 9
Study 33084524 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 9
Study 32109991 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-Dose Combination (FDC) of amlodipine/losartan/rosuvastatin 5/100/20 mg
Number of subjects: 60
Study 32109991 — intervention group
Group type: COMPARATOR
Intervention: Loose Combination (LC) of amlodipine/losartan and rosuvastatin
Number of subjects: 60
Study 35597226 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (10 Hz, 100% of resting motor threshold)
Number of subjects: 44
Study 35597226 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 44
Study 35597226 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 44
Study 33025056 — intervention group
Group type: EXPERIMENTAL
Intervention: Unloading brace
Number of subjects: 21
Study 33025056 — intervention group
Group type: COMPARATOR
Intervention: No-brace group
Number of subjects: 21
Study 32486256 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich fish oil capsules (2 g per day, 860 mg DHA + 120 mg EPA)
Number of subjects: 58
Study 32486256 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 58
Study 36940782 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-printed model
Number of subjects: 184
Study 36940782 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D printed picture
Number of subjects: 184
Study 33657420 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube eyes
Number of subjects: 419
Study 33657420 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy eyes
Number of subjects: 419
Study 33657420 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT IRIS Registry tube eyes
Number of subjects: 419
Study 33657420 — intervention group
Group type: COMPARATOR
Intervention: TVT RCT tube eyes
Number of subjects: 419
Study 32658503 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Neurofeedback Training (NFT), 24 sessions, twice a week
Number of subjects: 37
Study 32658503 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual control
Number of subjects: 37
Study 36384746 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers (telmisartan 40 mg/day)
Number of subjects: 787
Study 36384746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 787
Study 34664527 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 100 mg/day for 12 weeks
Number of subjects: 55
Study 34950221 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiaoyutang combined with intraperitoneal heat perfusion chemotherapy
Number of subjects: 96
Study 34950221 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal thermal perfusion chemotherapy (Control)
Number of subjects: 96
Study 32968008 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional status including anthropometric measurements, dietary intakes from complementary foods, feeding practices, and micronutrient concentrations.
Number of subjects: 0
Study 32968008 — intervention group
Group type: COMPARATOR
Intervention: Consumption of fats and oils the previous day.
Number of subjects: 0
Study 32968008 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive nutritional status (growth, nutritional blood biomarkers, dietary intakes, and feeding practices).
Number of subjects: 0
Study 34701532 — intervention group
Group type: EXPERIMENTAL
Intervention: GC4711 (100 mg IV prior to each of 5 consecutive daily SBRT fractions of 10-12Gy)
Number of subjects: 71
Study 34701532 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in the Phase 2 cohort concurrent with SBRT)
Number of subjects: 71
Study 34701532 — intervention group
Group type: EXPERIMENTAL
Intervention: SBRT (5 fractions of 10-12Gy)
Number of subjects: 71
Study 35766657 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir
Number of subjects: 252
Study 35766657 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Number of subjects: 252
Study 35766657 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Number of subjects: 252
Study 35766657 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir, Daclatasvir, or Sofosbuvir (in combination)
Number of subjects: 252
Study 35766657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 32833476 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress reactivity assessment
Number of subjects: 0
Study 32833476 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact of stress reactivity on temporal discounting
Number of subjects: 0
Study 32833476 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to cancer control behaviors and treatment compliance
Number of subjects: 0
Study 33432635 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Overuse Treatment Strategy trial
Number of subjects: 610
Study 33432635 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher headache frequency
Number of subjects: 610
Study 33432635 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine preventive medication
Number of subjects: 610
Study 32291802 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-amplification hearing aids (active)
Number of subjects: 13
Study 32291802 — intervention group
Group type: COMPARATOR
Intervention: Low-amplification hearing aids (sham)
Number of subjects: 13
Study 35951066 — intervention group
Group type: EXPERIMENTAL
Intervention: Reiki therapy (21 sessions)
Number of subjects: 0
Study 35951066 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 0
Study 32348605 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular methylprednisolone acetate (MPA) 100 mg/joint
Number of subjects: 12
Study 32348605 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular methylprednisolone acetate (MPA) 200 mg
Number of subjects: 12
Study 36278451 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery-focused therapy plus treatment as usual
Number of subjects: 39
Study 36278451 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 39
Study 32014845 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (mHealth team challenge)
Number of subjects: 40
Study 32014845 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 35285308 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT Angiography (OCT-A)
Number of subjects: 64
Study 35285308 — intervention group
Group type: COMPARATOR
Intervention: OCT B-scan (OCT-B)
Number of subjects: 64
Study 33951306 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot reflexology
Number of subjects: 20
Study 32101269 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG group (laparoscopic gastrectomy using near‐infrared imaging after endoscopic peritumoral injection of ICG 1 day before surgery)
Number of subjects: 258
Study 32101269 — intervention group
Group type: COMPARATOR
Intervention: Non‐ICG group (conventional laparoscopic gastrectomy)
Number of subjects: 258
Study 32101269 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG group
Number of subjects: 258
Study 32101269 — intervention group
Group type: COMPARATOR
Intervention: Non‐ICG group
Number of subjects: 258
Study 33794675 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity‐informed bolus method
Number of subjects: 15
Study 33794675 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (ST)
Number of subjects: 15
Study 34919132 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrographic seizure group (ESG) - treated for both electrographic and clinical seizures
Number of subjects: 212
Study 34919132 — intervention group
Group type: COMPARATOR
Intervention: Clinical seizure group (CSG) - treated only for clinically detected seizures
Number of subjects: 212
Study 34919132 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrographic seizure group (ESG)
Number of subjects: 212
Study 34919132 — intervention group
Group type: COMPARATOR
Intervention: Clinical seizure group (CSG)
Number of subjects: 212
Study 34919132 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes (time to suck feeds, seizure burden, brain injury score)
Number of subjects: 212
Study 35879573 — intervention group
Group type: EXPERIMENTAL
Intervention: bc‐EIS
Number of subjects: 95
Study 35879573 — intervention group
Group type: COMPARATOR
Intervention: EVL
Number of subjects: 95
Study 32869428 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated Hybrid Coating (TEOS/GPTMS/Y‐APS)
Number of subjects: 30
Study 32869428 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted Hybrid Coating (1:3 ratio with distilled water)
Number of subjects: 30
Study 32869428 — intervention group
Group type: COMPARATOR
Intervention: Control (Saliva)
Number of subjects: 30
Study 36322060 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 248
Study 36322060 — intervention group
Group type: COMPARATOR
Intervention: Sham Electroacupuncture (SA)
Number of subjects: 248
Study 32597289 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Number of subjects: 17
Study 32597289 — intervention group
Group type: COMPARATOR
Intervention: PBS
Number of subjects: 17
Study 32080123 — intervention group
Group type: EXPERIMENTAL
Intervention: Jujadokseo-hwan (JDH)
Number of subjects: 0
Study 32080123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36180059 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-driven rapid response team protocol for suspected sepsis
Number of subjects: 32
Study 34143234 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation anesthesia (IAA) with sevoflurane treatment
Number of subjects: 180
Study 34143234 — intervention group
Group type: COMPARATOR
Intervention: Intravenous anesthesia (IVA) with propofol treatment
Number of subjects: 180
Study 32841251 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal nontransmitted haplotype score for height
Number of subjects: 10734
Study 32841251 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal transmitted height haplotype scores
Number of subjects: 10734
Study 32841251 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal transmitted BMI scores
Number of subjects: 10734
Study 32841251 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal and paternal transmitted BP scores
Number of subjects: 10734
Study 32841251 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontransmitted haplotype score for FPG
Number of subjects: 10734
Study 32841251 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotype scores for T2D
Number of subjects: 10734
Study 32841251 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal transmitted birth weight score
Number of subjects: 10734
Study 35974352 — intervention group
Group type: EXPERIMENTAL
Intervention: SCT-based training program consisting of six 60-80 min sessions followed by 2-3 follow-up home visits (once a month for each participant)
Number of subjects: 106
Study 35974352 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 106
Study 33844642 — intervention group
Group type: EXPERIMENTAL
Intervention: rhLf
Number of subjects: 36
Study 33844642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 33284679 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (400 mg/d for 3 days followed by 200 mg/d for 11 days)
Number of subjects: 829
Study 33284679 — intervention group
Group type: COMPARATOR
Intervention: Ascorbic acid (500 mg/d followed by 250 mg/d) as a placebo‐equivalent control
Number of subjects: 829
Study 33284679 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 829
Study 32498269 — intervention group
Group type: EXPERIMENTAL
Intervention: Porphyra tenera extract (PTE) 2.5 g/day for 8 weeks
Number of subjects: 120
Study 32498269 — intervention group
Group type: COMPARATOR
Intervention: Placebo (crystal cellulose capsules) for 8 weeks
Number of subjects: 120
Study 32498269 — intervention group
Group type: EXPERIMENTAL
Intervention: Porphyra tenera extract (PTE) 2.5 g/day for 8 weeks (subgroup analysis of 101 subjects without URI)
Number of subjects: 120
Study 37573352 — intervention group
Group type: EXPERIMENTAL
Intervention: In-centre nocturnal haemodialysis (INHD), 6 to 8 hours thrice-weekly for 6 months
Number of subjects: 68000
Study 37573352 — intervention group
Group type: COMPARATOR
Intervention: Conventional haemodialysis (thrice-weekly daytime in-centre haemodialysis, 3.5–5 hours per session)
Number of subjects: 68000
Study 34852414 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequate use of protocol and adherence (identified as a cause of AEs)
Number of subjects: 650
Study 34852414 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical analysis (descriptive and inferential statistics including confirmatory factor analysis)
Number of subjects: 650
Study 32195863 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper lateral cartilage classified from class I to class V
Number of subjects: 71
Study 35394961 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-level PLATE
Number of subjects: 46
Study 35394961 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-level CAGE
Number of subjects: 46
Study 35394961 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-level PLATE
Number of subjects: 46
Study 35394961 — intervention group
Group type: COMPARATOR
Intervention: 1-level CAGE
Number of subjects: 46
Study 32179874 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 23
Study 32179874 — intervention group
Group type: EXPERIMENTAL
Intervention: Household income
Number of subjects: 23
Study 32179874 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprivation index
Number of subjects: 23
Study 32054510 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational booklet with foot-related exercises (3 times/week for 8 weeks)
Number of subjects: 48
Study 32054510 — intervention group
Group type: COMPARATOR
Intervention: Recommended foot care by international consensus (no foot exercises)
Number of subjects: 48
Study 34407342 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant pembrolizumab (200 mg intravenously once every 3 weeks for up to 17 cycles)
Number of subjects: 994
Study 34407342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 994
Study 34407342 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant pembrolizumab
Number of subjects: 994
Study 32299400 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Reports (SR)
Number of subjects: 104
Study 32299400 — intervention group
Group type: COMPARATOR
Intervention: Free-Text Reports (FTR)
Number of subjects: 104
Study 35118684 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled trials in pediatric population
Number of subjects: 71
Study 35118684 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled trials in adult population
Number of subjects: 71
Study 33538409 — intervention group
Group type: EXPERIMENTAL
Intervention: Planning condition (formed one FV plan)
Number of subjects: 206
Study 33538409 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 206
Study 32427795 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Empowerment Intervention (HEI) consisting of 6 weekly sessions based on the Health Empowerment Theory
Number of subjects: 20
Study 32427795 — intervention group
Group type: COMPARATOR
Intervention: Attention Control
Number of subjects: 20
Study 35881414 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-oriented training
Number of subjects: 18
Study 35881414 — intervention group
Group type: COMPARATOR
Intervention: Conventional Therapy
Number of subjects: 18
Study 33862045 — intervention group
Group type: EXPERIMENTAL
Intervention: HIC (Hepatic Insulin Clearance)
Number of subjects: 3311
Study 33862045 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver fat
Number of subjects: 3311
Study 33862045 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI-related SNPs
Number of subjects: 3311
Study 33862045 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein
Number of subjects: 3311
Study 33862045 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL
Number of subjects: 3311
Study 33156995 — intervention group
Group type: COMPARATOR
Intervention: Reference product (metronidazole cream)
Number of subjects: 10
Study 33156995 — intervention group
Group type: COMPARATOR
Intervention: 0.56% MTZ cream (negative control)
Number of subjects: 10
Study 33156995 — intervention group
Group type: COMPARATOR
Intervention: 0.95% MTZ cream (negative control)
Number of subjects: 10
Study 33156995 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% MTZ cream
Number of subjects: 10
Study 34171823 — intervention group
Group type: EXPERIMENTAL
Intervention: AFGE-AD (integrated, minimal-guidance, adherence-focused self-help intervention)
Number of subjects: 689
Study 34171823 — intervention group
Group type: EXPERIMENTAL
Intervention: AFGE-AO (self-help intervention designed to reduce alcohol use only)
Number of subjects: 689
Study 34171823 — intervention group
Group type: COMPARATOR
Intervention: IAU (internet access as usual)
Number of subjects: 689
Study 32311911 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 μg of the β2‐agonist salbutamol
Number of subjects: 18
Study 32311911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 32311911 — intervention group
Group type: COMPARATOR
Intervention: Filtered air (FA)
Number of subjects: 18
Study 32311911 — intervention group
Group type: COMPARATOR
Intervention: Diesel exhaust (DE)
Number of subjects: 18
Study 36420278 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-degree reverse Trendelenburg position
Number of subjects: 60
Study 36420278 — intervention group
Group type: COMPARATOR
Intervention: Recumbent position (Group 1)
Number of subjects: 60
Study 32648391 — intervention group
Group type: EXPERIMENTAL
Intervention: Herb-separated moxibustion at Jinsuo (GV 8)-eight-diagram points, applied for 40 min once daily for 8 weeks.
Number of subjects: 126
Study 32648391 — intervention group
Group type: COMPARATOR
Intervention: Pinaverium bromide tablets, 50 mg three times a day for 8 weeks.
Number of subjects: 126
Study 32648391 — intervention group
Group type: COMPARATOR
Intervention: Tongxieyaofang decoction, one dose a day for 8 weeks, taken separately in two times.
Number of subjects: 126
Study 35781437 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mouthwash
Number of subjects: 20
Study 35781437 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 20
Study 32051193 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating linoleic acid
Number of subjects: 24000
Study 32051193 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating α-linolenic acid
Number of subjects: 24000